BioNTech raises FY25 revenue view to EUR 2.6B-EUR 2.8B from EUR 1.7B-EUR 2.2B

BioNTech (BNTX) has increased its previous revenue guidance and now expects its revenues for the full 2025 financial year to be in the range of EUR 2,600 – EUR 2,800 million. With regards to COVID-19 vaccine franchise, the guidance reflects the following assumptions: relatively stable COVID-19 vaccine pricing and market share as compared to 2024; inventory write-downs and other charges estimated to be approximately 15% of BioNTech’s share of gross profit from COVID-19 vaccine sales in Pfizer’s (PFE) territory; and anticipated revenues from a pandemic preparedness contract with the German government. Current and potential further developments in law, global public policy, international trade, and public sentiment as they continue to evolve could further impact the anticipated COVID-19 vaccine revenues and expenses. The revenue guidance also includes anticipated revenues from collaborations, and from the BioNTech Group service businesses.